The prize given by MERCK-SHARP-DHOME ARGENTINA and THE MINISTRY OF SCIENCE, TECHNOLOGY AND INNOVATION rewards the most talented Start-ups and health technology based companies from Argentina with potential of global impact.
Immunalgia Therapeutics is committed into an ambitious project that is focus on the development of a new drug product based on synthetic non-coding oligonucleotides, which continuously proves to be highly efficient and safe, in the control of inflammatory and neuropathic pain in pre-clinical trials.
Important steps have been taken to transform these molecules into effective drugs for the treatment of chronic pain so far, a disease that affects approx. 30% of the world’s population. In this sense, the doses schemes of the candidate IMT molecule were validated in different experimental models of pain, tested in pre-clinical toxicity studies and comply with all the stages of the pharmaceutical development. In the short term, Immunlagia is focused on conducting clinical studies of safety and efficacy in patients, to reduce technological risk and put the company in value. In the long term, it will focus on generating benefits for the community, for the company and for our potential strategic partners.